These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 12377974)

  • 1. Cautious arguments in favor of body surface area-based dosing.
    Schuler U
    J Clin Oncol; 2002 Oct; 20(20):4270; author reply 4270-1. PubMed ID: 12377974
    [No Abstract]   [Full Text] [Related]  

  • 2. Flat-fixed dosing versus body surface area based dosing of anticancer drugs: there is a difference.
    Hempel G; Boos J
    Oncologist; 2007 Aug; 12(8):924-6. PubMed ID: 17766651
    [No Abstract]   [Full Text] [Related]  

  • 3. The scientific basis of body surface area-based dosing.
    Chatelut E; Puisset F
    Clin Pharmacol Ther; 2014 Apr; 95(4):359-61. PubMed ID: 24646485
    [No Abstract]   [Full Text] [Related]  

  • 4. Body surface area in dosing anticancer agents: scratch the surface!
    Miller AA
    J Natl Cancer Inst; 2002 Dec; 94(24):1822-3. PubMed ID: 12488468
    [No Abstract]   [Full Text] [Related]  

  • 5. Conventional dosing of anticancer agents: precisely wrong or just inaccurate?
    Bins S; Ratain MJ; Mathijssen RH
    Clin Pharmacol Ther; 2014 Apr; 95(4):361-4. PubMed ID: 24646486
    [No Abstract]   [Full Text] [Related]  

  • 6. Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.
    Loos WJ; Gelderblom H; Sparreboom A; Verweij J; de Jonge MJ
    Clin Cancer Res; 2000 Jul; 6(7):2685-9. PubMed ID: 10914710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of body weight and body surface area in dosing of anticancer agents in adult patients].
    Levêque D
    Bull Cancer; 2007 Jul; 94(7):647-51. PubMed ID: 17723945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?
    Mathijssen RH; de Jong FA; Loos WJ; van der Bol JM; Verweij J; Sparreboom A
    Oncologist; 2007 Aug; 12(8):913-23. PubMed ID: 17766650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Getting the right dose in cancer chemotherapy--time to stop using surface area?
    Newell DR
    Br J Cancer; 2002 Apr; 86(8):1207-8. PubMed ID: 11953873
    [No Abstract]   [Full Text] [Related]  

  • 10. Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma.
    Shepherd ST; Gillen G; Morrison P; Forte C; Macpherson IR; White JD; Mark PB
    Eur J Cancer; 2014 Mar; 50(5):944-52. PubMed ID: 24445148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
    Miller AA; Rosner GL; Egorin MJ; Hollis D; Lichtman SM; Ratain MJ
    Clin Cancer Res; 2004 Dec; 10(24):8325-31. PubMed ID: 15623609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.
    Smorenburg CH; Sparreboom A; Bontenbal M; Stoter G; Nooter K; Verweij J
    J Clin Oncol; 2003 Jan; 21(2):197-202. PubMed ID: 12525510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dose expression of antineoplastic drugs].
    Favre R; Duffaud F; Erard G
    Rev Med Interne; 1996; 17(7):586-96. PubMed ID: 8881387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA).
    Hunter RJ; Navo MA; Thaker PH; Bodurka DC; Wolf JK; Smith JA
    Cancer Treat Rev; 2009 Feb; 35(1):69-78. PubMed ID: 18922643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors.
    Tan AR; Moore DF; Hidalgo M; Doroshow JH; Poplin EA; Goodin S; Mauro D; Rubin EH
    Clin Cancer Res; 2006 Nov; 12(21):6517-22. PubMed ID: 17065274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.
    Ando Y; Ohtsu T; Ando M; Ohyanagi F; Nagashima F; Narabayashi M; Saijo N; Sasaki Y
    J Natl Cancer Inst; 2003 Nov; 95(21):1638-40. PubMed ID: 14600098
    [No Abstract]   [Full Text] [Related]  

  • 17. A cross-sectional study comparing variation in body surface area and chemotherapy dosing in pediatric oncology using two different methods.
    Jastaniah W; Aseeri M
    J Oncol Pharm Pract; 2010 Sep; 16(3):189-93. PubMed ID: 19808711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The next (third) dimension to dosing of anticancer agents.
    Vriesendorp HM
    J Clin Oncol; 1998 Nov; 16(11):3715-6. PubMed ID: 9817296
    [No Abstract]   [Full Text] [Related]  

  • 19. PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing.
    Mross K; Holländer N; Frost A; Unger C; Ziroli V; Massing U
    Onkologie; 2006 Oct; 29(10):444-50. PubMed ID: 17028453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
    Cassidy J; Twelves C; Cameron D; Steward W; O'Byrne K; Jodrell D; Banken L; Goggin T; Jones D; Roos B; Bush E; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 1999; 44(6):453-60. PubMed ID: 10550565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.